4,393 Shares in The Clorox Company (NYSE:CLX) Purchased by Pallas Capital Advisors LLC

Pallas Capital Advisors LLC acquired a new position in The Clorox Company (NYSE:CLX) during the 1st quarter, according to its most recent filing with the SEC. The fund acquired 4,393 shares of the company’s stock, valued at approximately $647,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Farther Finance Advisors LLC boosted its position in shares of Clorox by 25.4% in the 1st quarter. Farther Finance Advisors LLC now owns 5,872 shares of the company’s stock worth $869,000 after buying an additional 1,190 shares in the last quarter. Toth Financial Advisory Corp raised its stake in Clorox by 23.5% in the 1st quarter. Toth Financial Advisory Corp now owns 18,741 shares of the company’s stock valued at $2,760,000 after purchasing an additional 3,564 shares during the last quarter. Courier Capital LLC raised its stake in Clorox by 11.6% in the 1st quarter. Courier Capital LLC now owns 2,785 shares of the company’s stock valued at $410,000 after purchasing an additional 290 shares during the last quarter. Wedge Capital Management L L P NC raised its stake in Clorox by 33.5% in the 1st quarter. Wedge Capital Management L L P NC now owns 28,510 shares of the company’s stock valued at $4,198,000 after purchasing an additional 7,159 shares during the last quarter. Finally, Park Avenue Securities LLC acquired a new position in Clorox in the 1st quarter valued at about $258,000. 78.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CLX has been the subject of several analyst reports. Morgan Stanley cut their target price on shares of Clorox from $165.00 to $150.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 6th. UBS Group cut their target price on shares of Clorox from $176.00 to $154.00 and set a “neutral” rating for the company in a research note on Thursday, April 17th. JPMorgan Chase & Co. cut their target price on shares of Clorox from $151.00 to $144.00 and set a “neutral” rating for the company in a research note on Tuesday, May 6th. Evercore ISI set a $140.00 target price on shares of Clorox and gave the company an “underperform” rating in a research note on Tuesday, May 6th. Finally, Barclays cut their target price on shares of Clorox from $134.00 to $129.00 and set an “underweight” rating for the company in a research note on Wednesday, May 7th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, Clorox currently has an average rating of “Hold” and a consensus price target of $151.23.

Insider Buying and Selling

In other Clorox news, Director Pierre R. Breber bought 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 7th. The stock was purchased at an average price of $136.57 per share, with a total value of $546,280.00. Following the transaction, the director now owns 4,000 shares in the company, valued at $546,280. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.57% of the company’s stock.

Clorox Trading Down 0.5%

Shares of CLX stock opened at $126.26 on Thursday. The firm has a market cap of $15.56 billion, a P/E ratio of 34.50, a PEG ratio of 2.62 and a beta of 0.54. The Clorox Company has a 1-year low of $125.77 and a 1-year high of $171.37. The company has a debt-to-equity ratio of 20.52, a current ratio of 0.94 and a quick ratio of 0.60. The firm’s 50-day simple moving average is $135.41 and its 200-day simple moving average is $149.05.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.12). The company had revenue of $1.67 billion for the quarter, compared to analysts’ expectations of $1.74 billion. Clorox had a return on equity of 316.87% and a net margin of 6.38%. The company’s revenue was down 8.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.71 earnings per share. As a group, equities analysts forecast that The Clorox Company will post 7.15 EPS for the current year.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.